US-based medical device company Penumbra has commercially introduced its thrombectomy device, the ACE 68 Reperfusion Catheter in the US.
The catheter is based on the latest technology to offer maximum aspiration power in an easy and safe way for extracting thrombus in acute ischemic stroke patients.
The device features a coil winding geometry along 16 transitions to promote an optimum tracking profile which is done through tortuosity characterising an acute ischemic stroke in patients.
It is designed to extract the clot quickly and effectively as a part of the Penumbra system.
Semmes-Murphey Neurologic & Spine Institute Department of Neurosurgery, UTHSC professor Adam Arthur said: “The ACE68 provides an opportunity to reverse strokes faster and with less expense.
“The larger lumen seems to allow better clot capture, which may reduce the need for adjunctive devices, simplify the procedure and reduce procedure cost important considerations as hospitals look to expand stroke services.”
The ACE68 Reperfusion Catheter is a part of the fully integrated Penumbra System used for revascularisation of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease after displaying of symptom within eight hours.
Penumbra chairman and chief executive officer Adam Elsesser said: "We designed the ACE68 with the intent to make real improvement on stroke procedure time, outcome and cost.
"The early reports from physicians on the performance of ACE68 confirm that this is the most impactful stroke product we have ever developed."
The Penumbra System is integrated with large, highly pliable and trackable Reperfusion Catheters that leverages on the full aspiration power of the Penumbra Pump MAX within an integrated, patented system to eliminate chances of the stroke-causing occlusion safely and effectively.
Image: The ACE6 8 Reperfusion Catheter. Photo: courtesy of Penumbra.